A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia
A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia
复制标题
DOI：
10.1016/s0145-2126(96)00108-7
复制
发表时间：
1997-05-01
影响因子：
2.7
通讯作者：
Wiernik, PH
中科院分区：
文献类型：
--
作者：
Dutcher, JP;Coletti, D;Wiernik, PH
本文报告用普卡霉素静脉滴注加α-干扰素皮下注射治疗13例慢性粒细胞白血病加速期患者。2例患者病情稳定，3例患者出现部分血液学缓解，1例患者出现血液学缓解伴主要细胞遗传学缓解。两名患者，进展对羟基脲，没有反应，但表现出再致敏的羟基脲诱导治疗完成后，并延长返回到慢性期为30个月和25个月。4名无应答者随后接受了额外的化疗并有应答。所有研究患者从CML加速期发展的中位生存期为24个月：显著长于其他报告的系列（中位生存期为6个月）。普卡霉素似乎增加了干扰素在CML加速期稳定中的功效。(C)1997 Elsevier Science Ltd.
Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML. (C) 1997 Elsevier Science Ltd.